ClinicalTrials.gg
Active, not recruitingNCT06054113Updated Nov 2, 2026

Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

A Phase 2 interventional study of Blinatumomab in B Precursor Acute Lymphoblastic Leukemia and Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia, sponsored by Amgen. Active, not recruiting at 7 sites in China. Open to participants aged 1 Month to 204 Months. Per ClinicalTrials.gov, last updated 2026-11-02.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Updated Nov 2, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
1 Month to 204 Months
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of blinatumomab.

02

Conditions studied

  • B Precursor Acute Lymphoblastic Leukemia
  • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • Relapsed/Refractory B precursor Acute Lymphoblastic Leukemia
  • R/R B-ALL
  • Blinatumomab
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 204 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant's parent or legally authorized representative has provided when the participant is legally too young to provide informed consent and the participant has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated
  • Pediatric participants aged > 1 month and \< 18 years at the time of informed consent
  • or/refractory precursor B-cell acute lymphoblastic leukemia (ALL) disease, defined as ≥5% bone marrow blasts with at least one of the following:
  • Second or later bone marrow relapse;
  • Any marrow relapse after hematopoietic stem cell transplant (alloHSCT);
  • Refractory to other treatments:
  • For participants in first relapse: failure to achieve a complete remission (CR) following a full standard reinduction chemotherapy regimen
  • For participants who have not achieved a first remission, failure to achieve remission following a full standard induction regimen
  • performance status ≥ 50% for participants ≥ 16 years
  • Lansky performance status ≥ 50% for participants \< 16 years

Exclusion criteria

Exclusion Criteria:

- Evidence of current central nervous system (CNS) involvement by ALL. Participants with CNS disease at the time of relapse are eligible if CNS is successfully treated prior to enrollment.

Other Medical Conditions

  • CNS pathology requiring treatment (eg, unstable epilepsy).
  • Isolated extramedullary (EM) disease.
  • Active other than ALL.
  • Burkitt's leukemia according to the World Health Organization (WHO) 2016 criteria.
  • Abnormal renal or hepatic function at screening as defined below:
  • Abnormal serum creatinine based on age/gender as described by Threshold Creatinine Values
  • Direct > 1.5 mg/dl (25.6 μmol/L) at screening (unless related to Gilbert's or Meulengracht disease).
  • Symptoms and/or clinical signs and/or radiological and/or sonographic signs that indicate an acute or uncontrolled chronic infection, any other concurrent disease or medical condition that could be exacerbated by the treatment or would seriously complicate compliance with the protocol.
  • Known infection with (HIV) or chronic infection with virus (hepatitis B surface antigen [HBsAg] positive) or virus (HCV) (anti-HCV positive).
  • Known to blinatumomab or any of the products or components of the blinatumomab formulation.

Prior/Concomitant Therapy

  • AlloHSCT within 12 weeks prior to start of protocol-specified therapy.
  • Active acute or chronic Graft-versus-Host-Disease (GvHD) requiring systemic treatment with medication.
  • Radiotherapy within 2 weeks prior to start of protocol-specified therapy.
  • Immunotherapy (eg, rituximab) within 4 weeks prior to start of protocol-specified therapy. Prior failed cluster of differentiation 19 (CD19) directed therapy such as prior blinatumomab or CD19 chimeric antigen receptor T cells (CAR T cell) will be allowed (with demonstrated continued CD19+ expression) if treatment ended > 4 weeks prior to start of protocol-specified therapy.
  • Cancer chemotherapy within 2 weeks before the start of protocol-specified therapy. With the exception of intrathecal chemotherapy and/or low dose maintenance therapy for example vinca alkaloids, mercaptopurine, methotrexate, or hydroxyurea or pre-phase chemotherapy and/or dexamethasone. Any low dose chemotherapy as stated above must be discontinued before starting pre-phase.

Prior/Concurrent Clinical Study Experience

- Currently receiving treatment in another device or drug study, or less than 4 weeks since ending treatment on another investigational device or drug study(ies). Other investigational procedures while participating in this study are excluded.

Other Exclusions

  • Female participants of with a positive pregnancy test assessed at Screening by a highly sensitive urine or serum pregnancy test.
  • Female participants who are breastfeeding or who plan to breastfeed while on study through 12 months after the last dose of protocol-required treatment with highest teratogenic risk.
  • Female participants of childbearing potential unwilling to use protocol-specified method of during treatment and for an additional 12 months after the last dose of protocol-required treatment with highest teratogenic risk.
  • Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment and for an additional 6 months after the last dose of protocol-required therapy with highest teratogenic risk.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
  • Female participants planning to become pregnant while on study through 12 months after the last dose of protocol-required treatment with highest teratogenic risk.
  • Male participants unwilling to abstain from donating sperm during treatment and for an additional 6 months after the last dose of protocol-required treatment with highest teratogenic risk.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Blinatumomab

    Participants will receive up to 5 cycles of blinatumomab (cycle is 42 days), including a 28-day continuous intravenous infusion (CIVI) of blinatumomab and a 14-day treatment free interval.

    Drug: Blinatumomab

Interventions

  • Administered via CIVI

    Also known as: Blincyto®

06

What researchers measure

Primary outcomes

  1. Number of Participants with Complete Remission (CR)

    Time frame: Up to 84 days

  2. Number of Participants with CR with Partial Recovery of Peripheral Blood Counts (CRh)

    Time frame: Up to 84 days

Secondary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Time frame: Up to approximately 240 days

  2. Number of Participants with Serious TEAEs

    Time frame: Up to approximately 2 years

  3. Number of Participants with Treatment-related TEAEs

    Time frame: Up to approximately 240 days

  4. Number of Participants with Adverse Events of Interest

    Time frame: Up to approximately 240 days

  5. Steady State Concentration (Css) of Blinatumomab

    Time frame: Days 3, 8, 9 and 29

  6. Clearance of Blinatumomab

    Time frame: Days 3, 8, 9 and 29

  7. Overall Survival (OS) Rate

    Time frame: Up to approximately 2 years

  8. Relapse-Free Survival (RFS) Rate

    Time frame: Up to approximately 2 years

  9. Number of Participants who Receive Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT)

    Time frame: Up to approximately 2 years

  10. 100-day Mortality Rate After alloHSCT

    Time frame: Up to approximately 2 years

  11. Number of Participants with Anti-blinatumomab Antibody (ADA) Formation

    Time frame: Up to approximately 240 days

  12. Minimal Residual Disease (MRD) Response

    Time frame: Up to 84 days

07

Study locations

7 sites
08

References and documents

Publications

  • Davis KL, Yao CC, Zimmerman JAO, Rau RE. Immunotherapy in B-Cell Acute Lymphoblastic Leukemia. J Natl Compr Canc Netw. 2025 Dec;23(12):e257067. doi: 10.6004/jnccn.2025.7067. PubMed 41671463 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2024 to primary completion in Jan 2026, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 26, 2023
StartActual
Jul 23, 2024
Primary completionActual
Jan 6, 2026
CompletionEst.
Oct 14, 2027
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 5, 2026→Jan 6, 2026
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Primary completion Jan 5, 2026→Jan 6, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06054113
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Sep 26, 2023
Start date
Jul 23, 2024
Primary completion
Jan 6, 2026
Completion
Oct 14, 2027 (estimated)
Last update
Nov 2, 2026

Study contacts

MD
study director · Amgen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Blinatumomab

Start the discussion